Psoriasis and Cardiovascular Disease: Novel Mechanisms and Evolving Therapeutics
Current Atherosclerosis Reports
Cardiovascular disease; Dyslipidemia; Inflammation; Psoriasis
Purpose of Review: Psoriasis is a chronic inflammatory skin condition that is associated with increased cardiovascular risk compared to those without psoriasis. This review will cover emerging mechanisms of cardiovascular risk, key pathways targeted with biologic therapies, and the current evidence on therapies to modulate this risk in patients with psoriasis. Recent Findings: Recent scientific work has highlighted mechanisms that contribute to this enhanced risk, including the role of vascular endothelial dysfunction, platelet activation, dyslipidemia, and increased cardiometabolic comorbidities. Newer biologic and targeted synthetic therapies have transformed psoriasis treatment with high rates of clinical remission and durable skin disease control now possible. Epidemiological evidence suggests that many of these therapies may lower cardiovascular risk in psoriasis, although prospective interventional data is lacking (or mixed). Recently, caution has also been raised that some treatments may negatively affect cardiovascular risk. Summary: Overall, the current data suggests a positive or neutral ability to reduce cardiovascular risk for TNF, IL-17A, and IL-12/23p40 inhibitors, but current evidence remains conflicting for anti-IL-23/p19 and JAK inhibitors. More studies that include prospective cohorts, larger number of patients, treatment duration, and validated surrogate outcomes are needed to better evaluate the role of biologic therapies on cardiovascular risk in psoriasis.
Weber, B., Merola, J., Husni, M., Di Carli, M., Berger, J., & Garshick, M. (2021). Psoriasis and Cardiovascular Disease: Novel Mechanisms and Evolving Therapeutics. Current Atherosclerosis Reports, 23 (11). http://dx.doi.org/10.1007/s11883-021-00963-y